183 related articles for article (PubMed ID: 10211120)
1. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome.
Kumar-Singh S; Jacobs W; Dhaene K; Weyn B; Bogers J; Weyler J; Van Marck E
J Pathol; 1998 Nov; 186(3):300-5. PubMed ID: 10211120
[TBL] [Abstract][Full Text] [Related]
2. Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium.
Gulyás M; Hjerpe A
J Pathol; 2003 Apr; 199(4):479-87. PubMed ID: 12635139
[TBL] [Abstract][Full Text] [Related]
3. Growth factors regulate the expression profile of their syndecan co-receptors and the differentiation of mesothelioma cells.
Dobra K; Nurminen M; Hjerpe A
Anticancer Res; 2003; 23(3B):2435-44. PubMed ID: 12894525
[TBL] [Abstract][Full Text] [Related]
4. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression.
Kumar-Singh S; Weyler J; Martin MJ; Vermeulen PB; Van Marck E
J Pathol; 1999 Sep; 189(1):72-8. PubMed ID: 10451491
[TBL] [Abstract][Full Text] [Related]
5. Expression of genes coding for proteoglycans and Wilms' tumour susceptibility gene 1 (WT1) by variously differentiated benign human mesothelial cells.
Gulyás M; Dobra K; Hjerpe A
Differentiation; 1999 Oct; 65(2):89-96. PubMed ID: 10550542
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of mesothelioma cells is influenced by the expression of proteoglycans.
Dobra K; Andäng M; Syrokou A; Karamanos NK; Hjerpe A
Exp Cell Res; 2000 Jul; 258(1):12-22. PubMed ID: 10912783
[TBL] [Abstract][Full Text] [Related]
7. Expression of syndecan-1 is induced by differentiation and suppressed by malignant transformation of human keratinocytes.
Inki P; Larjava H; Haapasalmi K; Miettinen HM; Grenman R; Jalkanen M
Eur J Cell Biol; 1994 Feb; 63(1):43-51. PubMed ID: 8005104
[TBL] [Abstract][Full Text] [Related]
8. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis.
Kumar-Singh S; Segers K; Rodeck U; Backhovens H; Bogers J; Weyler J; Van Broeckhoven C; Van Marck E
J Pathol; 1997 Jan; 181(1):67-74. PubMed ID: 9072005
[TBL] [Abstract][Full Text] [Related]
9. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer.
Davies EJ; Blackhall FH; Shanks JH; David G; McGown AT; Swindell R; Slade RJ; Martin-Hirsch P; Gallagher JT; Jayson GC
Clin Cancer Res; 2004 Aug; 10(15):5178-86. PubMed ID: 15297422
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1.
Cook DM; Hinkes MT; Bernfield M; Rauscher FJ
Oncogene; 1996 Oct; 13(8):1789-99. PubMed ID: 8895526
[TBL] [Abstract][Full Text] [Related]
11. Developmental and FGF-2-mediated regulation of syndecans (1-4) and glypican in oligodendrocytes.
Bansal R; Kumar M; Murray K; Pfeiffer SE
Mol Cell Neurosci; 1996 Apr; 7(4):276-88. PubMed ID: 8793863
[TBL] [Abstract][Full Text] [Related]
12. Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas.
Saqi A; Yun SS; Yu GH; Alexis D; Taub RN; Powell CA; Borczuk AC
Diagn Cytopathol; 2005 Aug; 33(2):65-70. PubMed ID: 16007640
[TBL] [Abstract][Full Text] [Related]
13. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer.
Joensuu H; Anttonen A; Eriksson M; Mäkitaro R; Alfthan H; Kinnula V; Leppä S
Cancer Res; 2002 Sep; 62(18):5210-7. PubMed ID: 12234986
[TBL] [Abstract][Full Text] [Related]
14. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells.
Matsuda K; Maruyama H; Guo F; Kleeff J; Itakura J; Matsumoto Y; Lander AD; Korc M
Cancer Res; 2001 Jul; 61(14):5562-9. PubMed ID: 11454708
[TBL] [Abstract][Full Text] [Related]
15. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma.
Rintala M; Inki P; Klemi P; Jalkanen M; Grénman S
Gynecol Oncol; 1999 Dec; 75(3):372-8. PubMed ID: 10600292
[TBL] [Abstract][Full Text] [Related]
16. Syndecan-1 expression has prognostic significance in head and neck carcinoma.
Anttonen A; Kajanti M; Heikkilä P; Jalkanen M; Joensuu H
Br J Cancer; 1999 Feb; 79(3-4):558-64. PubMed ID: 10027330
[TBL] [Abstract][Full Text] [Related]
17. Expression of syndecan-1 changes during the differentiation of visceral and parietal endoderm from murine F9 teratocarcinoma cells.
Jiang R; Kato M; Bernfield M; Grabel LB
Differentiation; 1995 Nov; 59(4):225-33. PubMed ID: 8575644
[TBL] [Abstract][Full Text] [Related]
18. Heparan sulphate proteoglycan expression in human primary liver tumours.
Roskams T; De Vos R; David G; Van Damme B; Desmet V
J Pathol; 1998 Jul; 185(3):290-7. PubMed ID: 9771483
[TBL] [Abstract][Full Text] [Related]
19. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.
Andersen NF; Standal T; Nielsen JL; Heickendorff L; Borset M; Sørensen FB; Abildgaard N
Br J Haematol; 2005 Jan; 128(2):210-7. PubMed ID: 15638855
[TBL] [Abstract][Full Text] [Related]
20. Expression and characterization of minican, a recombinant syndecan-1 with extensively truncated core protein.
Viklund L; Loo BM; Hermonen J; El-Darwish K; Jalkanen M; Salmivirta M
Biochem Biophys Res Commun; 2002 Jan; 290(1):146-52. PubMed ID: 11779146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
